The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

the therapy’s mechanism of action aims to address this unmet need with its nonselective, noncompetitive antagonist of the NMDA receptor. Approved in 77 countries, esketamine is indicated for ...

Ketamine-assisted therapy lifted me out of depression. But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help ...

Esketamine may be an option for people with ... Like Winograd, she’d tried many antidepressants over the years. Ketamine therapy helped her depression and PTSD, but not her anxiety.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Like any drug, esketamine isn’t without its risks ... Still, Spravato’s expansion into a standalone therapy means that more people with treatment-resistant depression will be able to access ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...